Dexcom's Trading Volume Drops 35% Ranking 355th Amidst Strong Q1 Results and Strategic Milestones

On June 20, 2025, Dexcom's trading volume reached $249 million, a 35.19% decrease from the previous day, ranking 355th in the day's stock market. Dexcom's stock price fell by 1.25%, marking the third consecutive day of decline, with a total decrease of 3.61% over the past three days.

Dexcom reported strong first-quarter 2025 results, driven by robust category demand, record new patient growth, and significant progress in long-term strategic initiatives. The company's strong commercial execution, expanding access footprint, and pipeline innovation position it well for long-term growth. However, effective logistics, regulatory compliance, and payer strategy will be crucial for converting these advantages into sustainable margin expansion.

One of the major milestones for Dexcom in 2025 is the significant expansion in reimbursement coverage for people with type 2 diabetes, particularly those not on insulin. By summer 2025, Dexcom’s G7 continuous glucose monitor will be covered by all three major pharmacy benefit managers for anyone with diabetes, unlocking access for nearly 6 million non-insulin users. This policy change has already led to a material increase in new starts from this cohort, the highest in Dexcom’s history. Physician prescribing patterns are also shifting, setting the stage for accelerating patient adoption in the latter half of the year.

Additionally, Dexcom’s over-the-counter CGM, Stelo, is helping capture a broader audience, including patients with prediabetes and those interested in wellness and metabolic health. The company has rolled out app enhancements, launched on Amazon, and observed a rising subscription trend among early adopters. While still in its early stages, Stelo adds a consumer-facing channel that complements the prescription-based G7 ecosystem.

The upcoming launch of the 15-Day G7 system marks a technological leap for Dexcom. With improved accuracy and extended wear time, the device is expected to bolster gross margins and deepen product differentiation. Integration efforts with insulin pump partners and payer contracting are already underway to ensure a seamless rollout in the second half of 2025.